Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwan Bezard

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
The Lancet. Neurology|February 24, 2017
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an updateValerie Voon, T Celeste Napier, Michael J Frank, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 6, 2013
Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonismJulien Pierre Dupuis, Michael Feyder, Cristina Miguelez, et al.
Neurobiology of Disease|March 14, 2015
D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassemblyPedro Barroso-Chinea, Marie-Laure Thiolat, Simone Bido, et al.
Neurobiology of Disease|April 15, 2014
Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategiesPierre-Olivier Fernagut, Benjamin Dehay, Aline Maillard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 13, 2016
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's diseaseAnnalisa Pinna, Wai Kin D Ko, Giulia Costa, et al.
Journal of Medicinal Chemistry|June 9, 2021
Adenosine A<sub>2A</sub>R/A<sub>1</sub>R Antagonists Enabling Additional H<sub>3</sub>R Antagonism for the Treatment of Parkinson's DiseaseStefanie Hagenow, Anna Affini, Elsa Y Pioli, et al.
Bioconjugate Chemistry|November 15, 2018
Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative DiseasesGeoffrey Prévot, Federico N Soria, Marie-Laure Thiolat, et al.
Neurobiology of Disease|April 16, 2017
In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brainsFabio Cavaliere, Loic Cerf, Benjamin Dehay, et al.
Communications Biology|November 25, 2025
Alzheimer's Tau seeds-induced pathology enhances hippocampal extracellular diffusionJuan Estaún-Panzano, Anna Lovisotto, Claire Mazzocco, et al.
Aging Cell|March 23, 2022
Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal functionMarie-Laure Arotcarena, Federico N Soria, Anthony Cunha, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
The Lancet. Neurology|February 24, 2017
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an updateValerie Voon, T Celeste Napier, Michael J Frank, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 6, 2013
Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonismJulien Pierre Dupuis, Michael Feyder, Cristina Miguelez, et al.
Neurobiology of Disease|March 14, 2015
D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassemblyPedro Barroso-Chinea, Marie-Laure Thiolat, Simone Bido, et al.
Neurobiology of Disease|April 15, 2014
Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategiesPierre-Olivier Fernagut, Benjamin Dehay, Aline Maillard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 13, 2016
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's diseaseAnnalisa Pinna, Wai Kin D Ko, Giulia Costa, et al.
Journal of Medicinal Chemistry|June 9, 2021
Adenosine A<sub>2A</sub>R/A<sub>1</sub>R Antagonists Enabling Additional H<sub>3</sub>R Antagonism for the Treatment of Parkinson's DiseaseStefanie Hagenow, Anna Affini, Elsa Y Pioli, et al.
Bioconjugate Chemistry|November 15, 2018
Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative DiseasesGeoffrey Prévot, Federico N Soria, Marie-Laure Thiolat, et al.
Neurobiology of Disease|April 16, 2017
In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brainsFabio Cavaliere, Loic Cerf, Benjamin Dehay, et al.
Communications Biology|November 25, 2025
Alzheimer's Tau seeds-induced pathology enhances hippocampal extracellular diffusionJuan Estaún-Panzano, Anna Lovisotto, Claire Mazzocco, et al.
Aging Cell|March 23, 2022
Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal functionMarie-Laure Arotcarena, Federico N Soria, Anthony Cunha, et al.
Pageof 30